Conformation-Dependent Interactions Between HIV-1 Envelope Glycoproteins and Broadly Neutralizing Antibodies

被引:0
|
作者
Flemming, Juliana [1 ]
Wiesen, Lisa [1 ]
Herschhorn, Alon [1 ]
机构
[1] Univ Minnesota, Dept Med, Div Infect Dis & Int Med, Room 2-101 MRF,689 23rd Ave SE, Minneapolis, MN 55455 USA
关键词
HIV-1; entry; HIV-1 envelope glycoproteins; conformational transitions; broadly neutralizing antibodies; HUMAN-IMMUNODEFICIENCY-VIRUS; PROXIMAL EXTERNAL-REGION; HUMAN MONOCLONAL-ANTIBODIES; GP120 INNER DOMAIN; CD4; BINDING-SITE; CD4-BOUND CONFORMATION; POTENT NEUTRALIZATION; GP41-GP120; INTERFACE; STRUCTURAL BASIS; TYPE-1; ENVELOPE;
D O I
10.1089/aid.2018.0102
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HIV type 1 (HIV-1) envelope glycoproteins (Env) mediate virus entry and are the target of neutralizing antibodies. Binding of the metastable HIV-1 Env trimer to the CD4 receptor triggers structural rearrangements that mediate Env conformational transitions from a closed conformation to a more open state through an intermediate step. Recent studies have revealed new insights on the dynamics, regulation, and molecular mechanisms of Env transitions along the entry pathway. In this study, we provide an overview of the current knowledge on Env conformational dynamics and the relationship between Env conformational states and neutralization selectivity of the broadly neutralizing antibodies that develop in 10%-20% of infected individuals and may provide guidance for the development of an effective HIV-1 vaccine.
引用
收藏
页码:794 / 803
页数:10
相关论文
共 50 条
  • [21] Are Broadly Neutralizing Antibodies against HIV-1 Unusual?
    Scott, Jamie Kathleen
    Wang, X.
    Wu, S.
    Lepik, C.
    Singh, H.
    Richman, D. D.
    Utz, P. J.
    Breden, F.
    JOURNAL OF IMMUNOLOGY, 2007, 178
  • [22] Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention
    Stephenson, Kathryn E.
    Wagh, Kshitij
    Korber, Bette
    Barouch, Dan H.
    ANNUAL REVIEW OF IMMUNOLOGY, VOL 38, 2020, 38 : 673 - 703
  • [23] Use of broadly neutralizing antibodies for HIV-1 prevention
    Pegu, Amarendra
    Hessell, Ann J.
    Mascola, John R.
    Haigwood, Nancy L.
    IMMUNOLOGICAL REVIEWS, 2017, 275 (01) : 296 - 312
  • [24] BROADLY NEUTRALIZING ANTIBODIES ELICITED BY THE HYPERVARIABLE NEUTRALIZING DETERMINANT OF HIV-1
    JAVAHERIAN, K
    LANGLOIS, AJ
    LAROSA, GJ
    PROFY, AT
    BOLOGNESI, DP
    HERLIHY, WC
    PUTNEY, SD
    MATTHEWS, TJ
    SCIENCE, 1990, 250 (4987) : 1590 - 1593
  • [25] HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development
    Verkoczy, Laurent
    Kelsoe, Garnett
    Haynes, Barton F.
    PLOS PATHOGENS, 2014, 10 (05)
  • [26] Association Between HIV-1 Coreceptor Usage and Resistance to Broadly Neutralizing Antibodies
    Pfeifer, Nico
    Walter, Hauke
    Lengauer, Thomas
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 67 (02) : 107 - 112
  • [27] Binding of Neutralizing Antibodies Results in Distinct Quaternary Conformations of Trimeric HIV-1 Envelope Glycoproteins
    Tran, Erin E. H.
    Kuybeda, Oleg
    Bartesaghi, Alberto
    Milne, Jacqueline L. S.
    Subramaniam, Sriram
    BIOPHYSICAL JOURNAL, 2013, 104 (02) : 352A - 352A
  • [28] Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
    Haynes, Barton F.
    Wiehe, Kevin
    Borrrow, Persephone
    Saunders, Kevin O.
    Korber, Bette
    Wagh, Kshitij
    McMichael, Andrew J.
    Kelsoe, Garnett
    Hahn, Beatrice H.
    Alt, Frederick
    Shaw, George M.
    NATURE REVIEWS IMMUNOLOGY, 2023, 23 (03) : 142 - 158
  • [29] Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
    Barton F. Haynes
    Kevin Wiehe
    Persephone Borrow
    Kevin O. Saunders
    Bette Korber
    Kshitij Wagh
    Andrew J. McMichael
    Garnett Kelsoe
    Beatrice H. Hahn
    Frederick Alt
    George M. Shaw
    Nature Reviews Immunology, 2023, 23 : 142 - 158
  • [30] Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection
    Cohen, Yehuda Z.
    Caskey, Marina
    CURRENT OPINION IN HIV AND AIDS, 2018, 13 (04) : 366 - 373